Details for New Drug Application (NDA): 202925
✉ Email this page to a colleague
The generic ingredient in CLOPIDOGREL BISULFATE is clopidogrel bisulfate. There are fifty-four drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the clopidogrel bisulfate profile page.
Summary for 202925
Tradename: | CLOPIDOGREL BISULFATE |
Applicant: | Accord Hlthcare |
Ingredient: | clopidogrel bisulfate |
Patents: | 0 |
Pharmacology for NDA: 202925
Mechanism of Action | Cytochrome P450 2C8 Inhibitors P2Y12 Receptor Antagonists |
Physiological Effect | Decreased Platelet Aggregation |
Suppliers and Packaging for NDA: 202925
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
CLOPIDOGREL BISULFATE | clopidogrel bisulfate | TABLET;ORAL | 202925 | ANDA | A-S Medication Solutions | 50090-2598 | 50090-2598-0 | 30 TABLET, FILM COATED in 1 BOTTLE (50090-2598-0) |
CLOPIDOGREL BISULFATE | clopidogrel bisulfate | TABLET;ORAL | 202925 | ANDA | A-S Medication Solutions | 50090-2598 | 50090-2598-1 | 90 TABLET, FILM COATED in 1 BOTTLE (50090-2598-1) |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 75MG BASE | ||||
Approval Date: | Mar 27, 2013 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 300MG BASE | ||||
Approval Date: | Mar 27, 2013 | TE: | RLD: | No |
Complete Access Available with Subscription